α-protein kinase 1 Inhibitors
α-protein kinase 1 inhibitors encompass a diverse group of chemical compounds that target various signaling pathways and kinases to indirectly modulate the activity of α-protein kinase 1. LY294002 and Wortmannin, both potent inhibitors of PI3K, work to diminish the PI3K/AKT pathway, leading to a decrease in the activation of downstream targets such as α-protein kinase 1. Similarly, Triciribine specifically targets AKT, further impeding the PI3K/AKT/mTOR signaling cascade, which is crucial for the regulation of α-protein kinase 1. The inhibition of mTOR by Rapamycin is another route through which α-protein kinase 1 activity can be suppressed, demonstrating the interconnected nature of these signaling pathways. Erlotinib and Sorafenib, by targeting EGFR and multiple tyrosine protein kinases respectively, including VEGFR and PDGFR, may indirectly influence α-protein kinase 1's activity by altering upstream signalingevents and their intersection with pathways that regulate α-protein kinase 1.
Additionally, compounds like PD98059 and U0126 target the MAPK/ERK pathway, a major signal transduction cascade that modulates various cellular processes, potentially including the activity of α-protein kinase 1. By preventing the activation of MEK1/2, these inhibitors impede the ERK-mediated phosphorylation events that could be essential for α-protein kinase 1 function. SB203580 and SP600125 extend the range of targeted pathways by inhibiting p38 MAP kinase and JNK, respectively, thus potentially affecting α-protein kinase 1 activity through alternative stress and cytokine response pathways. Tyrosine kinase inhibitors such as Imatinib and Dasatinib offer a broader spectrum of inhibition, targeting BCR-ABL, c-KIT, PDGFR, and SRC family kinases, which could indirectly attenuate α-protein kinase 1 activity through their respective signal transduction pathways. Through the collective inhibition exerted by these compounds on multiple pathways, the functional activity of α-protein kinase 1 can be strategically diminished, demonstrating the complexity and adaptability of cellular signaling networks.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A potent inhibitor of PI3K, LY294002 blocks the PI3K/AKT pathway. By inhibiting this pathway, the phosphorylation and activation of α-protein kinase 1, which may rely on PI3K signaling for its activation, can be reduced. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin specifically inhibits mTOR (mammalian target of rapamycin), which is a downstream component of the PI3K/AKT pathway. The inhibition of mTOR could lead to a decrease in α-protein kinase 1 activity due to the suppression of mTOR-mediated signaling events that can activate α-protein kinase 1. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
A specific inhibitor of MEK1/2, PD98059 blocks the MAPK/ERK pathway. By inhibiting this pathway, the potential downstream effects on α-protein kinase 1 activity, which might be regulated by ERK-mediated phosphorylation events, can be indirectly inhibited. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
This compound inhibits p38 MAP kinase, which is involved in cellular responses to cytokines and stress. Inhibition of p38 MAP kinase can alter signaling cascades that potentially influence the activity of α-protein kinase 1. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Another PI3K inhibitor, Wortmannin, also prevents AKT activation. By doing so, it can indirectly inhibit the activity of α-protein kinase 1 if its activation is dependent on the PI3K/AKT signaling pathway. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $85.00 $132.00 $287.00 $495.00 $3752.00 | 42 | |
Erlotinib is an EGFR tyrosine kinase inhibitor, which could indirectly affect α-protein kinase 1 activity by inhibiting EGFR signaling pathways that may crosstalk with pathways regulating α-protein kinase 1. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
As an inhibitor of MEK1/2, U0126 prevents the activation of the MAPK/ERK pathway. This can contribute to the decrease in α-protein kinase 1 activity if it is regulated by ERK downstream signaling. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of JNK (c-Jun N-terminal kinase), SP600125 may affect α-protein kinase 1 activity by modulating JNK-dependent pathways that could intersect with α-protein kinase 1 regulatory mechanisms. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib targets multiple tyrosine protein kinases such as VEGFR and PDGFR, and by inhibiting these receptors, it can potentially influence signaling pathways that modulate α-protein kinase 1 activity. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
Imatinib is a tyrosine kinase inhibitor that primarily targets BCR-ABL, c-KIT, and PDGFR. By inhibiting these kinases, it may indirectly affect α-protein kinase 1 through signal transduction pathways that overlap with its regulation. | ||||||